RxDoctor Payments Data

Dharmesh Shah, MD

Family Medicine · Chesapeake, VANPI 1942264775

Payments from drug & device makers

$3,443in general payments, 2019–2025

Across 235 payments — averaging $14.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$432
  • Pfizer$421
  • AstraZeneca$410
  • Merck$323
  • Novo Nordisk$317
  • Boehringer Ingelheim$262
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,42399%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,443 in reported general payments places this provider in the 80th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$40,669
Medicare patients
161
Services billed
402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin33$50,128
EliquisApixaban77$48,157
TrulicityDulaglutide22$33,916
OzempicSemaglutide17$29,085
XareltoRivaroxaban20$21,428
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$20,816
MounjaroTirzepatide15$15,990
Soliqua 100-33Insulin Glargine/Lixisenatide13$14,453
LinzessLinaclotide18$13,568
TrintellixVortioxetine Hydrobromide12$5,773
Combivent RespimatIpratropium/Albuterol Sulfate12$5,769
Breo ElliptaFluticasone/Vilanterol16$5,258
Incruse ElliptaUmeclidinium Bromide12$3,274
SynthroidLevothyroxine Sodium46$2,868
Colchicine26$2,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$262$55,89745 claims
Lilly USA, LLCTrulicity, Mounjaro$208$49,90637 claims
PfizerEliquis$421$48,15777 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$161$29,34850 claims
Novo NordiskOzempic$317$29,08517 claims
Johnson & JohnsonXarelto$28$21,42820 claims
AbbVieLinzess, Synthroid$217$16,43664 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$432$14,45313 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$18$5,77312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →